Stock MarketROI
Closed
TECH

TECH- Bio-Techne Corporation

Healthcare · Biotechnology

Price?
$72.27+0.21%
1Y Change?
-
P/E?
62.30
Last Dividend?
$0.08
Div Yield?
0.44%

Price & Performance

Performance

Analysis & Verdict

Analyst Ratings

Wall Street consensus from 11 analysts

12-Month Price Target

$70.73

-2.1% downside
Low $50.00High $73.00
Current $72.27 Avg target $70.73

Based on analyst estimates; price targets are opinions, not guarantees.

Fair Value Estimates

Current price: $72.27

Graham Number

√(22.5 × EPS × Book Value)

$18.78

-74.0% downside

Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.

Bazin Ceiling Price

Avg. Annual DPS (5Y) ÷ 6%

$5.33

-92.6% downside

Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.

These are simplified estimates. Not financial advice.

Buy & Hold Checklist

Quality criteria for long-term holding

7/10

78% score

Pays dividends

15Y hist.

15+ years of dividend history

Dividend consistency (5Y+)

15 yrs

Uninterrupted dividend payments for at least 5 years

ROE above 10%

9.0%

Return on equity - measures how efficiently capital is used

Positive profit margin

15.0%

Net profit margin must be positive - company earns more than it spends

Revenue growth (annual)

+1.3%

Annual revenue must be growing compared to the prior year

Earnings growth (annual)

Annual earnings must be growing compared to the prior year

Debt/Equity below 2×

13.71×

Low financial leverage reduces risk of distress

Current ratio above 1

4.55×

Short-term assets must cover short-term liabilities

Daily liquidity above $5M

$338M/day

High trading volume ensures easy entry and exit

Dividend yield above 0%

0.44%

Stock must distribute income to shareholders

Financials

Revenue & Results

Key Statistics

Market Cap$11.33B
P/E Ratio62.30
Forward P/E31.34
P/B Ratio-
PEG Ratio2.10

Earnings

Next Earnings

Nov 9, 2026

55

days

EPS (TTM)

$1.16

P/E (TTM)

62.3

Fwd P/E

31.3

SEC Filings & Reported Financials

Earnings History

SEC EDGAR · official filings

SEC filings

SEC Filings

Official EDGAR documents

All filings

Insider Transactions

SEC Form 4 · officers, directors & 10% owners

Dividends & Income

Dividends

Current DY

0.44%

5Y Avg Annual

$0.3040

Last Payment

$0.0800

Ex-Date

08/24/2026

Annual dividends paid per share

2011
2019
2026
Ex-DatePaymentAmountEst. DY
Latest08/24/2026
09/04/2026$0.08000.44%
05/18/2026
05/29/2026$0.08000.44%
02/13/2026
02/24/2026$0.08000.44%
11/17/2025
11/28/2025$0.08000.44%
08/18/2025
08/29/2025$0.08000.44%
05/19/2025
05/30/2025$0.08000.44%
02/14/2025
02/25/2025$0.08000.44%
11/08/2024
11/19/2024$0.08000.44%

Magic Number

Shares needed to self-fund your next purchase

$72.27

Price

÷

$0.0800

Last div. (quarterly)

=

904

shares

Own 904 TECH shares ($65,332.08) and each quarterly dividend pays for 1 new share - the snowball runs on its own.

Investment target

$65,332.08

New shares / year

+4 shares

Dividend Calculator

0.44% yield

Estimate TECH dividend income at the current rate.

$

Per year

$44.28

Per month

$3.69

138.4 shares at $0.32/share a year. Estimate only - dividends can be cut or raised.

Tools & Simulators

TECH vs Peers, Indexes & Commodities

?

Click a card below to plot it on the chart

Loading history…

If you had invested
$
you would have:

Parameters

$
$
%

Final value

$426,404.61

Total invested

$130,000.00

Total interest

$296,404.61

Balance over time

Final balanceInvested
Invested - 30.5%Interest earned - 69.5%

Period breakdown

PeriodBalanceInvestedInterest
Start$10,000.00$10,000.00$0.00
Year 1$17,270.27$16,000.00$1,270.27
Year 2$25,267.56$22,000.00$3,267.56
Year 3$34,064.59$28,000.00$6,064.59
Year 4$43,741.32$34,000.00$9,741.32
Year 5$54,385.72$40,000.00$14,385.72
Year 6$66,094.55$46,000.00$20,094.55
Year 7$78,974.28$52,000.00$26,974.28
Year 8$93,141.97$58,000.00$35,141.97
Year 9$108,726.44$64,000.00$44,726.44
Year 10$125,869.35$70,000.00$55,869.35
Year 11$144,726.56$76,000.00$68,726.56
Year 12$165,469.48$82,000.00$83,469.48
Year 13$188,286.70$88,000.00$100,286.70
Year 14$213,385.63$94,000.00$119,385.63
Year 15$240,994.47$100,000.00$140,994.47
Year 16$271,364.18$106,000.00$165,364.18
Year 17$304,770.87$112,000.00$192,770.87
Year 18$341,518.22$118,000.00$223,518.22
Year 19$381,940.31$124,000.00$257,940.31
Year 20$426,404.61$130,000.00$296,404.61

What is compound interest?

Compound interest means that the interest you earn in one period is added to your principal, so in the next period you earn interest on a larger base. This creates exponential growth: the longer your time horizon, the more dramatic the effect.

Which rate should I use?

The S&P 500 has historically returned ~10%/year before inflation over long periods - use this for an all-equity US index fund scenario. A balanced growth portfolio (stocks + bonds) is closer to 7%. High-yield savings accounts (HYSA) are currently paying around 4-5% with FDIC insurance and zero market risk. Bonds historically return ~4% annualized.

Formula used

FV = PV × (1+r)^n + PMT × ((1+r)^n − 1) / rwhere r is the monthly rate, n is the number of months, PV is the initial investment, and PMT is the monthly contribution. Annual rates are converted to monthly viar = (1 + annual%)^(1/12) − 1.

For educational purposes only. Not financial advice. Past returns do not guarantee future results.

Discussion

Sign in to join the discussionSign in

Loading…

Discover

Related Assets

Healthcare

View TECHoptions chain (calls, puts & IV)

Related Articles

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Sector

Healthcare

Industry

Biotechnology

Location

Minneapolis, United States

Employees

3,000

Listed on NasdaqGS

Stock Market ROI Pro

All features, zero ads- web & app

Unlock every feature, ad-free, across our website and iOS app.

Go Pro →

Bio-Techne Corporation (TECH) stock trades at $72.27, up 0.21% on the day. With a market capitalization of $11.33 billion, TECH is a large-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 62.3, a forward P/E of 31.3 and earnings per share (EPS) of $1.16. Over the most recent period the company reported 1% year-over-year revenue growth and a net profit margin of 15.0%. Below you'll find TECH's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.

TECH - Frequently Asked Questions

Is Bio-Techne Corporation (TECH) a good stock to buy in 2026?

Bio-Techne Corporation (TECH) shows risks such as a rich P/E of 62× and high leverage (debt/equity of 13.7). Whether TECH is a good buy in 2026 depends on your time horizon and risk tolerance - review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.

What is TECH's stock price today?

Bio-Techne Corporation (TECH) trades at $72.27, up 0.21% on the session. Prices on this page update throughout the trading day.

Does TECH pay a dividend?

Yes. Bio-Techne Corporation pays an annual dividend of $0.32 per share, a dividend yield of 0.44%. The most recent ex-dividend date was August 24, 2026. Its payout ratio is about 28% of earnings.

Is TECH overvalued?

With a P/E ratio of 62.3×, TECH trades at a premium valuation for the healthcare sector. Its PEG ratio is 2.10. See the Fair Value Estimates section above for Graham Number and dividend-based price targets.

What is TECH's market cap?

Bio-Techne Corporation (TECH) has a market capitalization of $11.33 billion, classifying it as a large-cap stock in the Healthcare sector.

Disclaimer: This page - including any buy/hold/avoid view, fair value or price estimate - is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.